Symptoms of persistent allergic rhinitis during a full calendar year in house dust mite‐sensitive subjects

Downie, Sue; Andersson, Morgan; Rimmer, Janet; Leuppi, Joerg D.; Xuan, Wei; Åkerlund, Anders; Peat, Jennifer K.; Salome, Cheryl M.

doi:10.1111/j.1398-9995.2003.00420.x

Cited by 81 publications

(114 citation statements)

References 20 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Overall 1170 citations were identified using the combination of the primary search terms with quality of life, of which 60 articles were associated with the different countries of interest. Further evaluation of the articles highlighted 28 articles , which were considered to be suitable for inclusion in the review (Table ).…”

Section: Resultsmentioning

confidence: 99%

Quality of life and control of allergic rhinitis in patients from regions beyond western Europe and the United States

Máspero¹,

Lee

Katelaris

et al. 2012

Clin Experimental Allergy

View full text Add to dashboard Cite

There is comparatively little information on health-related quality of life (HRQoL) in subjects with allergic rhinitis (AR) or allergic rhinoconjunctivitis (AR/C) in countries beyond western Europe and North America. The primary aim of this investigation was therefore to review and assess the information in the public domain on HRQoL in AR/C patients from diverse regions of the world, represented by different countries, including Argentina, Australia, Brazil, Russia, Singapore, South Africa and Turkey. Second, in view of the absence of a standardized definition for 'AR control', the review aimed to determine whether a working definition of AR/C can be inferred from validated tests or other instruments documented to date. Despite the comparatively low number of studies, this review demonstrated that overall the symptoms of AR/C impair the HRQoL of patients in these regions by adversely impacting sleep, daily activities, physical and mental status and social functioning, similar to that demonstrated in much larger numbers of studies of AR/C patients in Europe and the United States. Furthermore, the findings of the review suggest that 'overall' control of the disease should encompass reduction of nasal and ocular symptoms, as well as improvements in HRQoL, comorbid conditions and cognition. Although some instruments are currently available for measuring control of AR, none are capable of assessing all these aspects, emphasizing the need to develop appropriate new instruments.

show abstract

Section: Resultsmentioning

confidence: 99%

Quality of life and control of allergic rhinitis in patients from regions beyond western Europe and the United States

Máspero¹,

Lee

Katelaris

et al. 2012

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…TNSS is a validated symptom severity scoring system that measures each of the following symptoms: nasal congestion, nasal itching, sneezing, and rhinorrhea. A 4‐point scale is used (0 to 3) for each question, where 0 indicates no symptoms and 3 indicates intolerable symptoms that interfere with daily activity . TNSS is calculated by adding the sum of each score for a maximum of 12.…”

Section: Methodsmentioning

confidence: 99%

“…A 4-point scale is used (0 to 3) for each question, where 0 indicates no symptoms and 3 indicates intolerable symptoms that interfere with daily activity. 11 TNSS is calculated by adding the sum of each score for a maximum of 12. The mini-Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) is a 14-question validated QOL measure of 5 rhinoconjunctivitis dimensions (activities, practical problems, nose symptoms, eye symptoms, and other symptoms) and uses a scale of 0 to 6 for each question.…”

Section: Data Collectionmentioning

confidence: 99%

A preliminary report on the effect of gabapentin pretreatment on periprocedural pain during in‐office posterior nasal nerve cryoablation

Steele

Hoshal

Kim

et al. 2019

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background Posterior nasal nerve (PNN) cryoablation is a novel surgical technique to address allergic and nonallergic rhinitis. Periprocedural pain has been reported after PNN cryoablation and there are no standardized protocols for optimal in‐office local anesthesia. This study sought to evaluate the effect of gabapentin on patient discomfort following in‐office PNN cryoablation. Methods Multi‐institutional prospective analysis of patients undergoing in‐office PNN cryoablation for allergic or nonallergic rhinitis between March 2018 and April 2019. Patients received local anesthesia with or without 600 mg oral gabapentin 1 hour preprocedure. Rhinitis diagnosis, demographics, and baseline disease‐specific quality of life (mini‐Rhinoconjunctivitis Quality of Life Questionnaire [RQLQ] and Total Nasal Symptom Score [TNSS]) were recorded. Patient discomfort was measured by the pain visual analogue scale (VAS) posttreatment and rated 0 to 10 on an ordinal scale. Fisher's exact and Wilcoxon 2‐sample tests were used to evaluate differences between the 2 groups. Results A total of 26 patients were enrolled (gabapentin n = 15, control = 11). Baseline TNSS scores in the gabapentin vs control group were median [25th percentile to 75th percentile]) 10 (7.5 to 11.0) and 9 (6.0 to 10.0) (p = 0.35). Baseline Mini‐RQLQ scores in gabapentin vs control groups were 3.21 (2.0 to 4.0) and 2.92 (2.78 to 4.35) (p = 0.51). The median VAS pain scores at 5, 20, and 30 minutes in the gabapentin vs control group were 0.0 (0.0 to 2.0) vs 3.0 (1.0 to 4.0), 2.0 (0.0 to 3.0) vs 8.0 (6.0 to 10.0), and 1.0 (0.0 to 1.0) vs 5.0 (4.0 to 6.0) (p = 0.02, p = 0.0043, and p = 0.003, respectively). Conclusion Preprocedure gabapentin significantly reduces immediate and delayed postprocedural patient discomfort following PNN cryoablation.

show abstract

“…The symptoms of sneezing, rhinorrhea with nasal congestion can be seasonal or perennial affecting the quality of life, including sleep, social interaction, and work. [1][2][3][4] Antihistamines essentially remain the fundamental group of drugs in treatment of allergic rhinitis. They not only reduce the disease symptomatology but also improve quality of life.…”

Section: Introductionmentioning

confidence: 99%

Efficacy, safety and cost effectiveness of levocetrizine and ebastine in allergic rhinitis: a comparative study

Rao

Pai

Vaidya

et al. 2018

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Allergic rhinitis is a ubiquitous aliment affecting a large population of individuals. The mainstay of treatment includes antihistamines and topical steroids. With a large assortment available, the choice of the drugs needs to be non-random and evidenced based. Hence this study was undertaken to compare Levocetrezine and Ebastine in terms of efficacy, safety and cost effectiveness in treatment of allergic rhinitis.Methods: Newly diagnosed patients with allergic rhinitis were categorized into two groups and treated with Levocetrizine 5mg and Ebastine 20mg per day respectively. Severity of the symptoms at the commencement and at the end of second and the fourth weeks of therapy were assessed using a four-point Likert scale and assigning a Total Nasal Symptoms Score (TNSS). The primary efficacy measure was mean change from baseline TNSS at each follow up visit. Change in TNSS was compared using Independent sample test. Adverse effects in both the groups were compared using Chi square test. Cost effectiveness was inferred by calculation of the Average Cost Effectiveness Ratio.Results: A total of 159 patients 84 from Levocetrizine group (L group) and 75 from the Ebastine group (E group) were available for study. At the end of second week, the E group showed a better reduction in TNSS(p-0.04). However, both the groups showed similar reduction in TNSS at the concluding visit (p-value of 0.09). The incidence of adverse effects was significantly higher in the L than in E. Levocetrezine was found to be more cost effective than Ebastine.Conclusions: Levocterezine and Ebastine are equally efficacious in treatment of allergic rhinitis. Hence treatment will have to be personalized to the individual patients based on other factors such as adverse drug effects and cost effectiveness.

show abstract

Symptoms of persistent allergic rhinitis during a full calendar year in house dust mite‐sensitive subjects

Cited by 81 publications

References 20 publications

Quality of life and control of allergic rhinitis in patients from regions beyond western Europe and the United States

Quality of life and control of allergic rhinitis in patients from regions beyond western Europe and the United States

A preliminary report on the effect of gabapentin pretreatment on periprocedural pain during in‐office posterior nasal nerve cryoablation

Efficacy, safety and cost effectiveness of levocetrizine and ebastine in allergic rhinitis: a comparative study

Contact Info

Product

Resources

About